#ctla-4

[biolegend]

Have you heard about checkpoint inhibitor immunotherapies that can obliterate some cancers? Well have you also heard about some of their extreme side-effects? Learn about them here: http://www.biolegend.com/newsdetail/4315/

[medicomunicare]

La via molecolare CTLA4-IL23: un dialogo insospettato che apre nuove possibilità contro cancro e autoimmunità

Il sistema immunitario ha molti percorsi per proteggere il corpo dalle infezioni, ma a volte una risposta immunitaria iperattiva provoca malattie autoimmuni tra cui le malattie infiammatorie intestinali (IBD), la psoriasi, l’artrite reumatoide e la sclerosi multipla. L’interleuchina-23 (IL-23) è uno di questi fattori immunitari che combatte le infezioni ma è anche implicato in molte di queste…

View On WordPress

[larryhbernsteinme]

Cyclic Dinucleotides and Histone deacetylase inhibitors

Cyclic Dinucleotides and Histone deacetylase inhibitors

Cyclic Dinucleotides and Histone deacetylase inhibitors

Curators: Larry H. Bernsten, MD, FCAP and Aviva Lev-Ari, PhD, RN

LPBI

  New Class of Immune System Stimulants: Cyclic Di-Nucleotides (CDN): Shrink Tumors and bolster Vaccines, re-arm the Immune System’s Natural Killer Cells, which attack Cancer Cells and Virus-infected Cells

Reporter: Aviva Lev-Ari, PhD, RN

The Immunotherapeutics and Vaccine…

View On WordPress

[pastdaily]

Blood Red Shoes - Live At Paredes de Coura 2015 - Nights At The Roundtable: Festival Edition

Blood Red Shoes – Live At Paredes de Coura 2015 – Nights At The Roundtable: Festival Edition

Blood Red Shoes – A lot of sound from two people.

http://pastdaily.com/wp-content/uploads/2015/09/Blood-Red-Shoes-Live-At-Paredes-de-Coura-Festival-Aug.-19-2015.mp3

–Blood Red Shoes – Live At Paredes de Coura Festival, Portugal – Aug. 19, 2015 – Vodafone Radio –

Sticking around the Paredes de Coura Festival tonight with a set from Power-duo Blood Red Shoes, recorded on August 19th.

The duo from

View On WordPress

[radoncnews]

Tumor Immunotherapy Directed at PD-1

Different anti-cancer strategies attempting to interfere with immunresponses have been tested. Cancer takes advantage of the ability to hide from the immune system by blocking T-cell activation. Blockade of cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) by antibodies (ipilimumab or tremelimumab), and therefore enhancing T-cell activation provided the first evidence of improvement in overall survival for the treatment of patients with metastatic melanoma. Due to unregulated, generalised T-cell activation in the lypmh node (priming phase), clinically significant inflammatory or autoimmune toxic effects are seen in 20 to 30% of patients.

A new approach to counteract immune system suppression by targeting programmed death 1 (PD-1) receptor, another inhibitory T-cell receptor that is engaged by its ligands within the tumor microenvironment, was tested in two clinical trials. The increased selectivity for immune suppressive signals that are delivered directly by the cancer, together with the role of PD-1 in regulating predominantly the effector phase of T-cell responses, predicts that PD-1 inhibition will have fewer side effects and greater antitumor activity than CTLA-4 inhibition.

By LSch

http://www.ncbi.nlm.nih.gov/pubmed/22658126

http://www.ncbi.nlm.nih.gov/pubmed/22658127

http://www.ncbi.nlm.nih.gov/pubmed/22658128

Keywords: PD-1, CTLA-4, Immunotherapy, antibody, T-cell